Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P08559: Variant p.Tyr243Asn

Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial
Gene: PDHA1
Feedback?
Variant information Variant position: help 243 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Tyrosine (Y) to Asparagine (N) at position 243 (Y243N, p.Tyr243Asn). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and aromatic (Y) to medium size and polar (N) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In PDHAD. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 243 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 390 The length of the canonical sequence.
Location on the sequence: help ENNRYGMGTSVERAAASTDY Y KRGDFIPGLRVDGMDILCVR The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         ENNRYGMGTSVERAAASTDYYKRGDFIPGLRVDGMDILCVR

Chimpanzee                    ENNRYGMGTSVERAAASTDYYKRGDFIPGLRVDGMDILCVR

Mouse                         ENNRYGMGTSVERAAASTDYYKRGDFIPGLRVDGMDILCVR

Rat                           ENNRYGMGTSVERAAASTDYYKRGDFIPGLRVDGMDILCVR

Bovine                        ENNRYGMGTSVERAAASTDYYKRGDFIPGLRVDGMDILCVR

Caenorhabditis elegans        ENNGFGMGTTAERSSASTEYYTRGDYVPGIWVDGMDILAVR

Slime mold                    ENNKYGMGTSQKRSTAGHDFYTRGHYVAGLKVDGMDVFAVK

Baker's yeast                 ENNKYGMGTAASRSSAMTEYFKRGQYIPGLKVNGMDILAVY

Fission yeast                 ENNKYGMGTSAERSSAMTEFYKRGQYIPGLLVNGMDVLAVL

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 30 – 390 Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial
Modified residue 232 – 232 Phosphoserine; by PDK1
Modified residue 244 – 244 N6-acetyllysine; alternate
Modified residue 244 – 244 N6-succinyllysine; alternate
Mutagenesis 232 – 232 S -> A. Abolishes inactivation by phosphorylation; when associated with A-293 and A-300.
Helix 242 – 244



Literature citations
Pyruvate dehydrogenase deficiency. Clinical presentation and molecular genetic characterization of five new patients.
Matthews P.M.; Brown R.M.; Otero L.J.; Marchington D.R.; LeGris M.; Howes R.; Meadows L.S.; Shevell M.; Scriver C.R.; Brown G.K.;
Brain 117:435-443(1994)
Cited for: VARIANTS PDHAD ASN-243; ASN-315 AND HIS-378; VARIANT LEU-282;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.